Does GENMAB A/S ORDINARY SHARES (OTCMKTS:GNMSF) Have Gas After Even More Sellers Involved?

May 27, 2018 - By Winifred Garcia

Genmab A/S (OTCMKTS:GNMSF) Logo

The stock of GENMAB A/S ORDINARY SHARES (OTCMKTS:GNMSF) registered an increase of 3.71% in short interest. GNMSF’s total short interest was 645,200 shares in May as published by FINRA. Its up 3.71% from 622,100 shares, reported previously. With 400 shares average volume, it will take short sellers 1613 days to cover their GNMSF’s short positions. The short interest to GENMAB A/S ORDINARY SHARES’s float is 1.07%.

The stock decreased 12.10% or $24.75 during the last trading session, reaching $179.75. About 1,001 shares traded or 456.11% up from the average. Genmab A/S (OTCMKTS:GNMSF) has 0.00% since May 27, 2017 and is . It has underperformed by 11.55% the S&P500.

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company has market cap of $10.46 billion. The firm markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia ; and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM). It has a 52.67 P/E ratio. The Company’s products under development include Ofatumumab to treat CLL and follicular lymphoma; Ofatumumab (OMB157) for relapsing remitting multiple sclerosis; and Daratumumab to treat MM, Non-Hodgkin's lymphoma, and solid tumors, as well as natural killer/T-cell lymphoma, nasal type.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: